The FDA has approved the first in-class targeted therapy for metastatic pancreatic cancer, marking a significant milestone in oncology treatment. This breakthrough offers new hope for patients with one of the most aggressive and difficult-to-treat forms of cancer.
Background
Pancreatic cancer is one of the deadliest forms of cancer with a low 5-year survival rate, and metastatic cases have historically had very limited treatment options. Targeted therapies represent a growing class of cancer drugs that attack specific molecular targets rather than broadly damaging healthy cells.
- Source
- Hacker News (RSS)
- Published
- Aug 27, 2026 at 12:19 AM
- Score
- 8.0 / 10